Search results for "Metabolic parameters"

showing 2 items of 2 documents

A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-Obesity: A 6-Month Randomized, Doub…

2023

Pre-obesity is a condition that predisposes to the risk of developing obesity, cardiovascular diseases (CVD), and diabetes. Our previous study demonstrated that a Cynara cardunculus (L.) based nutraceutical named Altilix® (Bionap, Italy), containing chlorogenic acid and luteolin extracts, was able to improve several hepatic and cardio-metabolic parameters. Given this background, we conducted a post-hoc analysis of the Altilix® study in order to analyze the supplement’s effects in the subgroup of pre-obesity subjects on anthropometry (weight and waist circumference), glucose metabolism (HbA1C, HOMA-IR, and HOMA-β), lipid profile (total cholesterol, triglycerides, LDL-chole…

Nutrition and Dieteticschlorogenic acidpre-obesity; chlorogenic acid; luteolin; cardiometabolic parametersluteolinpre-obesitycardiometabolic parametersFood ScienceNutrients; Volume 15; Issue 2; Pages: 462
researchProduct

Analysis of Metabolic Parameters Coming from Basal and Interim PET in Hodgkin Lymphoma

2018

Objective: Positron Emission Tomography (PET) with F-18-Fluoro-deoxy-glucose (FDG) emerged as a prognostic tool to predict treatment outcome in Hodgkin Lymphoma (HL). Moreover, a FDG-PET adapted strategy is currently assessed in clinical trial to minimize the toxic effect while maintaining the efficacy of treatment in HL. Purpose was to analyze the quantitative parameters to support the prognostic role of FDG-PET today based on the semi-quantitative Deauville 5-point Scale (D5-PS). Methods: This retrospective study included 53 patients diagnosed with advanced-stage HL between 2009 and 2014, enrolled in the PET response-adapted clinical trial HD 0607. FDG-PET was performed at baseline (PET0)…

Pathologymedicine.medical_specialtyChemothrapy; FDG PET; Hodgkin lymphoma; Metabolic parameters; Metabolic tumor volume; Prognostic value; Radiology Nuclear Medicine and Imagingbusiness.industryHODGkin lymphomaMetabolic tumor volume02 engineering and technology021001 nanoscience & nanotechnologyInterim pet03 medical and health sciencesBasal (phylogenetics)0302 clinical medicineNuclear Medicine and ImagingFDG PETmedicineHodgkin lymphomaRadiology Nuclear Medicine and imaging030212 general & internal medicineMetabolic parametersRadiology0210 nano-technologyNuclear medicinebusinessPrognostic valueChemothrapyCurrent Medical Imaging Reviews
researchProduct